戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ecipients with a history of life-threatening alloimmunization.
2 ion and, (5) the treatment and prevention of alloimmunization.
3 proved oxygenation, with a 1 percent rate of alloimmunization.
4  at risk for anemia due to maternal red-cell alloimmunization.
5  at risk for anemia due to maternal red-cell alloimmunization.
6 ocytes provides a potential stimulus for HbA alloimmunization.
7 tic counseling and prenatal assessment of Rh alloimmunization.
8 nts should be considered to prevent platelet alloimmunization.
9  as a means of preventing the development of alloimmunization.
10 le effect on primary T-cell reactivity after alloimmunization.
11 a good serologic screen for the diagnosis of alloimmunization.
12 4 expression, thereby confirming its role in alloimmunization.
13 ody-mediated RBC removal can enhance de novo alloimmunization.
14 ssues in the care of pregnant women with RBC alloimmunization.
15 endritic cells (DCs), which are required for alloimmunization.
16 ti-CD20 Ab has recently been used to prevent alloimmunization.
17  responsible for sensing RBCs and triggering alloimmunization.
18 mit the further amplification of established alloimmunization.
19 mmatory conditions associated with increased alloimmunization.
20 oimmunization and for abolishing established alloimmunization.
21 major complication of transfusion therapy is alloimmunization.
22 antigen features that may also influence RBC alloimmunization.
23  of an adjuvant, is sufficient to induce RBC alloimmunization.
24 eceptor is required for inflammation-induced alloimmunization.
25  significantly decreased in Akita mice after alloimmunization.
26 c acid-induced IFN-alpha/beta production and alloimmunization.
27             Prophylactic protocols prevented alloimmunization.
28 inflammatory state that is less conducive to alloimmunization.
29 ted this hypothesis in a murine model of KEL alloimmunization.
30  unknown to what extent this occurs in human alloimmunization.
31 ens, whereas nonresponders were resistant to alloimmunization.
32 nicity is a crucial factor in red blood cell alloimmunization.
33 binding motif for HLA-DR52a that can lead to alloimmunization.
34 mental factors may play a role in regulating alloimmunization.
35 mmation has a complex regulatory effect upon alloimmunization.
36 mmation in mice has the capacity to regulate alloimmunization.
37 d the enhancing effects of poly (I:C) on RBC alloimmunization.
38 l leukocytes in blood transfusions can cause alloimmunization.
39 acid [poly (I:C)] significantly enhances RBC alloimmunization.
40 in 60%) proved to be effective in preventing alloimmunization (2.8% vs 33%; P =.0005).
41 alloimmunization was more prevalent than RBC alloimmunization (20% to 30%).
42  with such a microbe could predispose to RBC alloimmunization, a mouse model was developed using muri
43                                     However, alloimmunization after transfusion is more common with p
44 acellular antigens may facilitate subsequent alloimmunization against a surface RBC antigen.
45                                              Alloimmunization against RBCs can cause life-threatening
46            However, transfusions can trigger alloimmunization against transfused RBCs with serious cl
47 onexpressers, and this difference may affect alloimmunization and allograft function.
48                                              Alloimmunization and autoimmunization are common, seriou
49 We assessed protocols for preventing primary alloimmunization and for abolishing established alloimmu
50 m)IL-12 was given to C57BL/6 mice undergoing alloimmunization and found to transiently but profoundly
51 from transfusion or pregnancy, may result in alloimmunization and incompatible RBC clearance.
52 specificity, and transfusions are limited by alloimmunization and iron overload.
53     We used BALB/c donors (H-2(d)) to assess alloimmunization and islet transplantation outcomes in A
54 quiring transfusion with a very high risk of alloimmunization and life-threatening complications.
55 nfections, may have an increased risk of RBC alloimmunization and may benefit from personalized trans
56 r areas, are needed to better understand RBC alloimmunization and refine preventative strategies.
57 le blood group loci, potentially eliminating alloimmunization and significantly improving transfusion
58 used leukocytes is critical to prevention of alloimmunization and transfusion-induced graft-versus-ho
59 ved antimicrobials, the effects of recipient alloimmunization and variable cell dose.
60         Autoimmunization was associated with alloimmunization and with the absence of spleen (44% and
61  transfused blood has been shown to decrease alloimmunization, and genotyping for antigen matching ma
62 ion, neonatal sepsis, twin-twin transfusion, alloimmunization, and hemolytic disease.
63 tients to insufficient correction of anemia, alloimmunization, and organ iron overload (for which the
64 uspicion is required to initiate testing for alloimmunization, and the leading culprit in immune PR i
65 d acute lung injury, infection transmission, alloimmunization, and/or transfusion reactions.
66 RhD immunoglobulin (Ig) to decrease maternal alloimmunization (antibody-mediated immune suppression [
67 ients, but immune factors governing risk for alloimmunization are unknown.
68 c patient databases enabling us to model RBC alloimmunization as a stochastic process.
69 commonly used therapy but has limitations of alloimmunization, availability, and expense.
70  responders may exhibit an increased rate of alloimmunization because of prior immune priming toward
71    Transfusion resulted in iron overload and alloimmunization, but no infection.
72  the ability of Mirasol treatment to prevent alloimmunization by platelet transfusions in rats.
73 e efficiently shared across institutions, Rh alloimmunization can be mitigated, better treatments exi
74                                          RBC alloimmunization can present a special challenge to soli
75                                              Alloimmunization can present a virtually insurmountable
76                                       HPA-1a alloimmunization complicates 1 in 350 unselected pregnan
77   While anti-D prophylaxis prevents maternal alloimmunization, concerns regarding availability, overu
78 k of three complications of transfusion: HLA alloimmunization, cytomegalovirus transmission, and recu
79 ent antiviral responses lead to breakthrough alloimmunization despite immunoprophylaxis may have tran
80  with poly(I:C) led to breakthrough anti-KEL alloimmunization despite KELIg administration.
81                       Moreover, preoperative alloimmunization did not block tolerance induction or in
82                 Most cases of Rhesus D (RhD) alloimmunization due to pregnancy can be prevented by th
83                                              Alloimmunization during pregnancy occurs when a mother p
84 gh alloimmunization, with poly(I:C) inducing alloimmunization even in the absence of recipient type I
85 ity/mortality of HDFN, women at risk for RBC alloimmunization have few therapeutic options.
86              Cases had a positive history of alloimmunization, having received >/=1 RBC unit.
87           Controls had a negative history of alloimmunization, having received >/=20 RBC units.
88      Keywords included platelet transfusion, alloimmunization, hemorrhage, threshold and thrombocytop
89 easurements, but are instead associated with alloimmunization history.
90         Transfusions can lead to erythrocyte alloimmunization, however, with serious complications fo
91  the other a monoclonal antibody, to prevent alloimmunization in a novel preclinical mouse model of F
92 eral concerns, including the consequences of alloimmunization in chronically transfused patients and
93 rphism have over a 3-fold lower risk for RBC alloimmunization in comparison with patients without thi
94     Advances have been made in understanding alloimmunization in granulocyte transfusion recipients a
95  carry out studies of prophylaxis to prevent alloimmunization in HPA-1a-negative mothers.
96 the rate and the frequency of red blood cell alloimmunization in mouse models, may dictate responder/
97 report results of prospective monitoring for alloimmunization in our recent CBT experience.
98     These data describe the prevalence of Rh alloimmunization in patients with SCD transfused with ph
99 port findings from an observational study of alloimmunization in patients with sickle cell disease (S
100              Extended blood typing decreases alloimmunization in SCD but is not universally adopted.
101  patients and minority donors will reduce Rh alloimmunization in SCD needs to be examined.
102 therapeutic potential to prevent and inhibit alloimmunization in SCD patients.
103                             Risk factors for alloimmunization in SCD remain poorly understood.
104 on between genetic variation of FCGR and RBC alloimmunization in SCD.
105          This may provide a means to prevent alloimmunization in the setting of RBC transfusion and s
106 patients and in the donors contributed to Rh alloimmunization in this study.
107 olyclonal anti-KEL sera completely prevented alloimmunization in wild-type and single-knockout (KO) m
108 laxis with polyclonal anti-KEL sera prevents alloimmunization in wild-type recipients transfused with
109                                              Alloimmunization is a major problem for patients being c
110                         Red blood cell (RBC) alloimmunization is a serious complication of transfusio
111 ntly occurring phenomenon, prevention of HLA alloimmunization is an important management strategy.
112 g of the immune mechanisms that underlie RBC alloimmunization is critical if future strategies capabl
113                               Red blood cell alloimmunization is typically associated with the transp
114 bulin to prevent pregnancy associated anti-D alloimmunization, its mechanism of action remains elusiv
115 unologic consequences of transfusion such as alloimmunization may also be severe, resulting in acute
116                                     However, alloimmunization may be a concern with adjuvanted vaccin
117  background peptide responses independent of alloimmunization may contribute to K immunogenicity.
118 hat are at risk because of maternal red-cell alloimmunization, moderate and severe anemia can be dete
119   Managing refractoriness resulting from HLA alloimmunization necessitates the use of HLA antigen-mat
120 Under conditions where breakthrough anti-KEL alloimmunization occurred, KEL RBC consumption by inflam
121                       Fetal problems include alloimmunization, opioid exposure, fetal growth restrict
122  untransfused patients demonstrated platelet alloimmunization (P < .05).
123 indings provide the first evidence of an RBC alloimmunization pathway which is IFNAR independent and
124 er experience demonstrating that HLA class I alloimmunization predicts longer time to platelet engraf
125 n of RBCs is the primary strategy invoked in alloimmunization prevention.
126                                     However, alloimmunization rates can vary dramatically, as some pa
127                            As in humans, RBC alloimmunization rates in recipient mice are variable, w
128                               Red blood cell alloimmunization remains a barrier for safe and effectiv
129                               Red blood cell alloimmunization remains a major complication for transf
130 effect on SCD humoral response, specifically alloimmunization, remains unclear.
131 fractory to platelet transfusions because of alloimmunization require HLA-matched platelets, which is
132 tic understanding have demonstrated that RBC alloimmunization requires the IFN-alpha/-beta receptor (
133 RF) was strongly associated with a decreased alloimmunization risk (odds ratio [OR] 0.26, 95% confide
134 t donor RBC antigens, and valid estimates of alloimmunization risk are clinically important, but litt
135 l heme responsiveness maybe a determinant of alloimmunization risk in SCD.
136                                     Anti-KEL alloimmunization, serum cytokines, and consumption of th
137 t half century, although breakthrough anti-D alloimmunization still occurs in some treated females.
138 s or patients with a known predisposition to alloimmunization, such as those with sickle cell disease
139 childhood are associated with lower rates of alloimmunization than are seen in SCD, suggesting immune
140 s who had a splenectomy had a higher rate of alloimmunization than patients who did not have a splene
141 ts that has a dramatically increased risk of alloimmunization that appears to be genetically determin
142  cells, consistent with other studies of RBC alloimmunization that show extrafollicular-like response
143 ing mixed lymphocyte reactions as a model of alloimmunization, the authors assessed the effect of inf
144  platelet concentrates for prevention of HLA alloimmunization, the findings of this study support tha
145  To discuss how inflammation affects humoral alloimmunization to antigens on transfused red blood cel
146 ay a significant role in transfusion-induced alloimmunization to donor class-I MHC antigens.
147 MNL) are responsible for transfusion-induced alloimmunization to donor major histocompatability compl
148                     Human lymphocyte antigen alloimmunization to filter leukoreduced (F-LR) platelets
149                                              Alloimmunization to foreign Rh proteins (RhD and RhCE) o
150 cessary to avert the adverse consequences of alloimmunization to human leukocyte antigens, immunohema
151                         Red blood cell (RBC) alloimmunization to paternal antigens during pregnancy c
152 of the fetus and newborn (HDFN) is caused by alloimmunization to paternally derived RBC antigens.
153                       In the Trial to Reduce Alloimmunization to Platelets (TRAP) study, 101 of 530 p
154 given to 533 patients in the Trial to Reduce Alloimmunization to Platelets (TRAP).
155 MT, we wished to determine the prevalence of alloimmunization to platelets in transfused SCD patients
156               Results of the Trial to Reduce Alloimmunization to Platelets will be reported shortly a
157 a similar role of inflammation in regulating alloimmunization to RBCs.
158                                              Alloimmunization to red blood cell (RBC) antigens can si
159                                      Humoral alloimmunization to red blood cell (RBC) antigens is a c
160                   HDFN is caused by maternal alloimmunization to red blood cell (RBC) antigens.
161 s been most applied are fetal aneuploidy and alloimmunization to red blood cell antigens.
162 ently, three unique murine models of humoral alloimmunization to transfused RBCs have been described.
163  to investigate if similar biology regulates alloimmunization to transfused RBCs in humans.
164 sm by which viral-like inflammation enhances alloimmunization to transfused RBCs.
165  blood cell (RBC) transfusions can result in alloimmunization toward RBC alloantigens that can increa
166 velopment of refractoriness to transfusions, alloimmunization, transfusion reactions, the transmissio
167  variety of immunologic responses, including alloimmunization, transfusion-associated graft-versus-ho
168 onor for male recipient, donor parity, donor alloimmunization, viral serology, nucleated cell dose, C
169 te) and Asian recipients on the frequency of alloimmunization was determined.
170                                     Platelet alloimmunization was more prevalent than RBC alloimmuniz
171 minority of untransfused patients at risk of alloimmunization who would benefit from more extensively
172  we discuss the risk factors associated with alloimmunization with emphasis on possible mechanisms th
173 7BL/6 splenocytes taken 7 days after in vivo alloimmunization with irradiated BALB/c spleen cells.
174 tration was sufficient to cause breakthrough alloimmunization, with poly(I:C) inducing alloimmunizati

 
Page Top